Company intelligence / Profile preview

Opuntia

Copenhagen, Denmark

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Opuntia Bio is a Danish biotechnology company focused on the discovery and development of next-generation therapeutics for obesity and related metabolic disorders. Founded in 2023 by a team of former Novo Nordisk executives and scientists, the company leverages deep expertise in peptide chemistry and metabolic signaling. Opuntia Bio aims to develop highly effective and tolerable treatments that address the global obesity epidemic by optimizing incretin-based pathways. Currently in the pre-clinical stage, the company is backed by prominent European life science investors and is part of the thriving metabolic research cluster in the Medicon Valley region.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Opuntia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opuntia.

Explore the full profile